IMMU 114

Drug Profile

IMMU 114

Alternative Names: hL243; IMMU114

Latest Information Update: 12 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antigen-presenting-cell-modulators; HLA-DR antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 06 Dec 2016 Pharmacodynamics data from preclinical studies in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 02 Aug 2016 Phase-I development is ongoing for Chronic lymphocytic leukemia and Non-Hodgkin's Lymphoma in USA (NCT01728207; Immunomedics pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top